Neurones Raises Revenue Target to Above €900m as IT Services Recovery Gains Pace

Neurones Upgrades 2026 Sales Target After a Robust First Half

Neurones has lifted its full-year revenue target to “above €900 million”, the Nanterre-based IT services firm (ESN) announced on Thursday, reflecting a marked acceleration in demand during the second quarter. The upgrade follows a first half in which organic growth reached 6.9%, climbing from 5.6% in the first quarter to 8% between April and June.

The new objective replaces the previous “around €900 million” outlook given after Q1 and aligns Neurones with a broader uplift among French peers including Capgemini, Aubay, Sopra Steria and Alten, which have also recently raised annual guidance. The company confirmed it is still targeting an operating margin of “about 9%” for 2026, a 20-basis-point improvement on the prior year.

Despite the positive tone, the shares showed little reaction, as the upgraded numbers had already been factored in by the market. The modest new target implies only around 3% organic growth in the second half, well below the first-half pace, suggesting management remains cautious despite the improving trend.

What the Upgrade Reveals About the IT Services Sector Recovery

A Conservative Upgrade That Leaves Ample Upside

Neurones’ new revenue goal requires organic growth of roughly 3% in the second half, a conservative figure given the 8% rate achieved in Q2. This implies management is either baking in potential economic headwinds or simply choosing to under-promise. For investors, the gap between the recent run-rate and the official target creates a credible path to future beats if current demand momentum persists.

Margin Aspirations Signal Pricing Discipline

Alongside the revenue revision, the company confirmed its 2026 operating margin target of “about 9%”, up 20 basis points from the previous financial year. In an industry where high utilisation and pricing power are critical, this suggests Neurones is managing its cost base effectively and pushing back against price erosion—a positive signal for profitability even as the top line expands.

Sector Context: A Broad Recovery for French ESNs

Neurones’ results fit into a wider picture of French IT services firms emerging from two difficult years. Peers such as Capgemini and Aubay have also lifted annual forecasts, indicating a genuine, if still uneven, recovery in client spending on digital transformation. The strong Q2 numbers across the sector suggest that the rebound is gaining traction, though the precise sustainability will depend on the macroeconomic environment and corporate IT budgets for 2027.

What Neurones’ Guidance Means for Investors

• Track the implied H2 execution. The new target needs only low single-digit organic growth; watch for Q3 revenue data to see whether the 8% pace from Q2 is maintained—any continuation would signal that full-year numbers could end well above the official range.
• Compare margin progress against peers. With the 9% margin target now explicitly reiterated, investors should monitor semi-annual operating profit trends to confirm the 20bp improvement is materialising. A miss on this metric would raise questions about cost control despite the upbeat revenue story.
• Assess valuation relative to the conservative guidance. Since the market had already priced in the upgrade, the stock’s next catalyst likely lies in outperformance against the low bar that management has set. A re-rating would require evidence that the recovery is durable beyond the current cycle.
• Watch the competitive landscape. As larger players like Capgemini also report improving demand, any signs that Neurones is losing out on higher-value contracts or facing renewed price competition could pressure margins later in the year.